Raquel Lima
Name: Raquel Lima
E-mail: rlima@ipatimup.pt
Extension: 
225570700
Academic Degree: PhD


Raquel Lima
Raquel Lima
Member of
Lab Technician of Ipatimup Diagnostics


Short CV

Highlights

Supervisor of
Ana Chantre, Master Student (theoretical phase)
MSc student
Bárbara Alves, Master Student (theoretical phase)
MSc student

PI (running)

PI (closed)
First Author
 
C
IF
1. Lima RT, Sousa D, Paiva AM, Palmeira A, Barbosa J, Pedro M, Pinto MM, Sousa E, Vasconcelos MH
Modulation of Autophagy by a Thioxanthone Decreases the Viability of Melanoma Cells. Molecules (Basel, Switzerland) 21: 1343, 2016. [Article] 
 
2. Lima RT, Barron GA, Grabowska JA, Bermano G, Kaur S, Roy N, Helena Vasconcelos M, Lin PK
 PMID: 23092269.
 
3. Lima RT, Seca H, Palmeira A, Fernandes MX, Castro F, Correia-da-Silva M, Nascimento MS, Sousa E, Pinto M, Vasconcelos MH
 doi: 10.1111/cbdd.12109 PMID: 23350710.
 
4. Lima Raquel T., Nascimento M . S. José, Vasconcelos M. Helena
EBV-associated cancers: Strategies for targeting the virus Microbial pathogens and strategies for combating them: science, technology and education 3: 1608-1618, 2013. [] 
.
 
5. Lima RT, Seca H, Brás S, Nascimento MS, Vasconcelos MH
 doi: 10.1159/000323627 PMID: 21540588.
 
6. Lima RT, Seca H, Soares P, Nascimento MS, Vasconcelos MH
EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide. Journal of cellular biochemistry 112: 200-10, 2011. [Article] 
 doi: 10.1002/jcb.22920 PMID: 21069730.
 
.
 
Chemosensitization effects of XIAP downregulation in K562 leukemia cells. Journal of chemotherapy (Florence, Italy) 18: 98-102, 2006. [Article] 
 PMID: 16572900.
 
 
Senior Author
 
C
IF
1. Príncipe C, Dionísio de Sousa IJ, Prazeres H, Soares P, Lima RT
LRP1B: A Giant Lost in Cancer Translation. Pharmaceuticals (Basel, Switzerland) 14: ., 2021. [Review] 
 doi: 10.3390/ph14090836 PMID: 34577535.
 
2. Dionísio de Sousa IJ, Cunha AI, Saraiva IA, Portugal RV, Gimba ERP, Guimarães M, Prazeres H, Lopes JM, Soares P, Lima RT
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer. Pathobiology : journal of immunopathology, molecular and cellular biology 88: 400-411, 2021. [Article] 
 doi: 10.1159/000517372 PMID: 34689147.
 
3. Bizarro A, Ferreira IC, Sokovic M, van Griensven LJ, Sousa D, Vasconcelos MH, Lima RT
 
Send Email
From
To
Subject